Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T66665 | Target Info | |||
Target Name | Prostaglandin G/H synthase 2 (COX-2) | ||||
Synonyms |
Prostaglandin-endoperoxide synthase 2; Prostaglandin H2 synthase 2; PHS II; PGHS-2; PGH synthase 2; Cyclooxygenase-2; COX2; COX-2
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | PTGS2 | ||||
Biochemical Class | Paired donor oxygen oxidoreductase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Androgen receptor (AR) | Successful Target | ||||
UniProt ID | ANDR_HUMAN | |||||
Gene Name | AR | |||||
Synonyms |
Testosterone receptor; Nuclear receptor subfamily 3 group C member 4; NR3C4; Dihydrotestosterone receptor; DHTR
Click to Show/Hide
|
|||||
Representative Drug(s) | Indomethacin | Drug Info | EC50 = 0.14 nM | [1] | ||
Co-Target Name | Prostaglandin G/H synthase 1 (COX-1) | Successful Target | ||||
UniProt ID | PGH1_HUMAN | |||||
Gene Name | PTGS1 | |||||
Synonyms |
Prostaglandin-endoperoxide synthase 1; Prostaglandin H2 synthase 1; PHS 1; PGHS-1; PGH synthase 1; Cyclooxygenase-1; COX1; COX-1
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 2 nM | Click to Show More | [2] | ||
2 | Indomethacin | Drug Info | IC50 = 2 nM | [3] | ||
3 | Lumiracoxib | Drug Info | IC50 = 7 nM | [4] | ||
4 | Flurbiprofen | Drug Info | IC50 = 10 nM | [5] | ||
5 | Celecoxib | Drug Info | IC50 = 50 nM | [11] | ||
6 | Ibuprofen | Drug Info | IC50 = 290 nM | [16] | ||
7 | Naproxen | Drug Info | IC50 = 350 nM | [18] | ||
8 | Darbufelone | Drug Info | IC50 = 600 nM | [20] | ||
Co-Target Name | Carbonic anhydrase XII (CA-XII) | Successful Target | ||||
UniProt ID | CAH12_HUMAN | |||||
Gene Name | CA12 | |||||
Synonyms |
Tumor antigen HOM-RCC-3.1.3; Carbonic anhydrase 12; Carbonate dehydratase XII
Click to Show/Hide
|
|||||
Representative Drug(s) | Valdecoxib | Drug Info | Ki = 13 nM | Click to Show More | [6] | |
2 | Celecoxib | Drug Info | Ki = 18 nM | [7] | ||
Co-Target Name | Carbonic anhydrase II (CA-II) | Successful Target | ||||
UniProt ID | CAH2_HUMAN | |||||
Gene Name | CA2 | |||||
Synonyms |
Carbonic anhydrase C; Carbonic anhydrase 2; Carbonate dehydratase II; CAC
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | IC50 = 21 nM | Click to Show More | [8] | |
2 | Valdecoxib | Drug Info | IC50 = 43 nM | [9] | ||
Co-Target Name | Interleukin-8 (IL8) | Successful Target | ||||
UniProt ID | IL8_HUMAN | |||||
Gene Name | CXCL8 | |||||
Synonyms |
T-cell chemotactic factor; Protein 3-10C; Neutrophil-activating protein 1; NAP-1; Monocyte-derived neutrophil-activating peptide; Monocyte-derived neutrophil chemotactic factor; MONAP; MDNCF; IL8; IL-8; Granulocyte chemotactic protein 1; GCP-1; Emoctakin; Chemokine (C-X-C motif) ligand 8; C-X-C motif chemokine 8
Click to Show/Hide
|
|||||
Representative Drug(s) | Indomethacin | Drug Info | IC50 = 50 nM | Click to Show More | [10] | |
2 | Tolmetin | Drug Info | IC50 = 90 nM | [10] | ||
Co-Target Name | Dihydrodiol dehydrogenase type I (AKR1C3) | Successful Target | ||||
UniProt ID | AK1C3_HUMAN | |||||
Gene Name | AKR1C3 | |||||
Synonyms |
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Testosterone 17-beta-dehydrogenase 5; Prostaglandin F synthase; PGFS; KIAA0119; Indanol dehydrogenase; HSD17B5; HA1753; Dihydrodiol dehydrogenase 3; DDH1; DD3; DD-3; Chlordecone reductase homolog HAKRb; Aldo-keto reductase family 1 member C3; 3-alpha-hydroxysteroid dehydrogenase type 2; 3-alpha-HSD type II, brain; 3-alpha-HSD type 2; 17-beta-hydroxysteroid dehydrogenase type 5; 17-beta-HSD 5
Click to Show/Hide
|
|||||
Representative Drug(s) | Flufenamic Acid | Drug Info | IC50 = 50 nM | Click to Show More | [12] | |
2 | Indomethacin | Drug Info | IC50 = 100 nM | [1] | ||
3 | Naproxen | Drug Info | IC50 = 180 nM | [14] | ||
4 | Mefenamic acid | Drug Info | Ki = 300 nM | [17] | ||
Co-Target Name | Carbonic anhydrase VI (CA-VI) | Successful Target | ||||
UniProt ID | CAH6_HUMAN | |||||
Gene Name | CA6 | |||||
Synonyms |
Secreted carbonic anhydrase; Salivary carbonic anhydrase; Carbonic anhydrase 6; Carbonate dehydratase VI
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | Ki = 94 nM | Click to Show More | [13] | |
2 | Valdecoxib | Drug Info | Ki = 572 nM | [19] | ||
Co-Target Name | Carbonic anhydrase XIV (CA-XIV) | Successful Target | ||||
UniProt ID | CAH14_HUMAN | |||||
Gene Name | CA14 | |||||
Synonyms |
UNQ690/PRO1335; Carbonic anhydrase 14; Carbonate dehydratase XIV
Click to Show/Hide
|
|||||
Representative Drug(s) | Valdecoxib | Drug Info | Ki = 107 nM | Click to Show More | [6] | |
2 | Celecoxib | Drug Info | Ki = 689 nM | [13] | ||
Co-Target Name | Carbonic anhydrase IV (CA-IV) | Successful Target | ||||
UniProt ID | CAH4_HUMAN | |||||
Gene Name | CA4 | |||||
Synonyms |
Carbonic anhydrase 4; Carbonate dehydratase IV; CAIV
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | Ki = 290 nM | [15] | ||
Co-Target Name | Amyloid beta A4 protein (APP) | Successful Target | ||||
UniProt ID | A4_HUMAN | |||||
Gene Name | APP | |||||
Synonyms |
Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | IC50 = 630 nM | [21] | ||
Co-Target Name | Monoamine oxidase type A (MAO-A) | Successful Target | ||||
UniProt ID | AOFA_HUMAN | |||||
Gene Name | MAOA | |||||
Synonyms |
Monoamine oxidase A; Amine oxidase [flavin-containing] A
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | Ki = 710 nM | [22] | ||
Co-Target Name | Lactoylglutathione lyase (GLO1) | Clinical trial Target | ||||
UniProt ID | LGUL_HUMAN | |||||
Gene Name | GLO1 | |||||
Synonyms |
S-D-lactoylglutathione methylglyoxal lyase; Methylglyoxalase; Ketone-aldehyde mutase; Glyoxalase I; GlxI; Glx I; GLO1; Aldoketomutase
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | Ki = 5 nM | [23] | ||
Co-Target Name | Tissue factor (F3) | Successful Target | ||||
UniProt ID | TF_HUMAN | |||||
Gene Name | F3 | |||||
Synonyms |
Thromboplastin; TF; F3; Coagulation factor III; CD142 antigen
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | IC50 = 13.16 nM | [24] | ||
Co-Target Name | Carbonic anhydrase IX (CA-IX) | Clinical trial Target | ||||
UniProt ID | CAH9_HUMAN | |||||
Gene Name | CA9 | |||||
Synonyms |
Renal cell carcinoma-associated antigen G250; RCC-associated antigen G250; PMW1; P54/58N; Membrane antigen MN; MN; G250 antigen (MN/CA IX/G250); G250; Carbonic anhydrase 9; Carbonate dehydratase IX; CAIX
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | IC50 = 16 nM | Click to Show More | [8] | |
2 | Valdecoxib | Drug Info | IC50 = 27 nM | [8] | ||
Co-Target Name | Prostaglandin D2 receptor 2 (PTGDR2) | Clinical trial Target | ||||
UniProt ID | PD2R2_HUMAN | |||||
Gene Name | PTGDR2 | |||||
Synonyms |
PTGDR2; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CD294
Click to Show/Hide
|
|||||
Representative Drug(s) | Indomethacin | Drug Info | Ki = 50 nM | [25] | ||
Co-Target Name | Thromboxane-A synthase (TBXAS1) | Clinical trial Target | ||||
UniProt ID | THAS_HUMAN | |||||
Gene Name | TBXAS1 | |||||
Synonyms |
Thromboxane A2 synthase; TXS; TXA synthase; Cytochrome P450 5A1; CYP5A1; CYP5
Click to Show/Hide
|
|||||
Representative Drug(s) | Indomethacin | Drug Info | IC50 = 100 nM | [26] | ||
Co-Target Name | Prostaglandin E synthase (PTGES) | Clinical trial Target | ||||
UniProt ID | PTGES_HUMAN | |||||
Gene Name | PTGES | |||||
Synonyms |
p53-induced gene 12 protein; PIG12; PGES; PGE synthase; P53-induced apoptosis protein 12; Microsomal prostaglandin E synthase 1; Microsomal glutathione S-transferase 1-like 1; MPGES1; MPGES-1; MGST1L1; MGST1-L1
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | IC50 = 200 nM | Click to Show More | [27] | |
2 | Celecoxib | Drug Info | IC50 = 425 nM | [28] | ||
Co-Target Name | Stress-activated protein kinase 2a (p38 alpha) | Clinical trial Target | ||||
UniProt ID | MK14_HUMAN | |||||
Gene Name | MAPK14 | |||||
Synonyms |
SAPK2A; P38 mitogen activatedprotein kinase; P38 Mitogen-activatedprotein kinase alpha; Mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; MXI2; MAX-interacting protein 2; MAPK 14; MAP kinase p38alpha; MAP kinase p38 alpha; MAP kinase MXI2; MAP kinase 14; Cytokine suppressive anti-inflammatory drug-binding protein; Cytokine suppressive anti-inflammatory drug binding protein; CSPB1; CSBP2; CSBP1; CSBP; CSAID-binding protein; CSAID binding protein; CRK1
Click to Show/Hide
|
|||||
Representative Drug(s) | Etoricoxib | Drug Info | IC50 = 530 nM | Click to Show More | [29] | |
2 | Celecoxib | Drug Info | IC50 = 810 nM | [29] | ||
3 | RWJ-67657 | Drug Info | IC50 = 1000 nM | [33] | ||
Co-Target Name | Histone deacetylase 6 (HDAC6) | Clinical trial Target | ||||
UniProt ID | HDAC6_HUMAN | |||||
Gene Name | HDAC6 | |||||
Synonyms |
KIAA0901; JM21; HD6
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | IC50 = 643 nM | [30] | ||
Co-Target Name | Myeloperoxidase (MPO) | Clinical trial Target | ||||
UniProt ID | PERM_HUMAN | |||||
Gene Name | MPO | |||||
Synonyms |
MPO
Click to Show/Hide
|
|||||
Representative Drug(s) | Mefenamic acid | Drug Info | IC50 = 980 nM | [31] | ||
Co-Target Name | Soluble epoxide hydrolase (EPHX2) | Clinical trial Target | ||||
UniProt ID | HYES_HUMAN | |||||
Gene Name | EPHX2 | |||||
Synonyms |
Bifunctional epoxide hydrolase 2
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | IC50 ~ 1000 nM | Click to Show More | [32] | |
2 | Rofecoxib | Drug Info | IC50 ~ 1000 nM | [32] | ||
3 | Indomethacin | Drug Info | IC50 ~ 1000 nM | [32] | ||
Co-Target Name | Cytochrome c oxidase subunit 2 (MT-CO2) | Co-Target | ||||
UniProt ID | COX2_HUMAN | |||||
Gene Name | MT-CO2 | |||||
Synonyms |
Cytochrome c oxidase polypeptide II
Click to Show/Hide
|
|||||
Representative Drug(s) | Rofecoxib | Drug Info | IC50 = 20 nM | Click to Show More | [34] | |
2 | Celecoxib | Drug Info | IC50 = 293 nM | [34] | ||
3 | Indomethacin | Drug Info | IC50 = 610 nM | [36] | ||
Co-Target Name | Carbonic anhydrase VB (CA5B) | Co-Target | ||||
UniProt ID | CAH5B_HUMAN | |||||
Gene Name | CA5B | |||||
Synonyms |
Carbonic anhydrase 5B, mitochondrial; Carbonate dehydratase VB; Carbonic anhydrase VB; CA-VB
Click to Show/Hide
|
|||||
Representative Drug(s) | Valdecoxib | Drug Info | Ki = 88 nM | Click to Show More | [6] | |
2 | Celecoxib | Drug Info | Ki = 93 nM | [6] | ||
Co-Target Name | Carbonic anhydrase XIII (CA13) | Co-Target | ||||
UniProt ID | CAH13_HUMAN | |||||
Gene Name | CA13 | |||||
Synonyms |
Carbonic anhydrase 13; Carbonate dehydratase XIII; CA-XIII
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | Ki = 98 nM | Click to Show More | [13] | |
2 | Valdecoxib | Drug Info | Ki = 425 nM | [6] | ||
Co-Target Name | CDGSH iron-sulfur domain-containing protein 1 (CISD1_HUMAN) | Co-Target | ||||
UniProt ID | CISD1_HUMAN | |||||
Gene Name | CISD1 | |||||
Synonyms |
MitoNEET
Click to Show/Hide
|
|||||
Representative Drug(s) | Curcumin | Drug Info | Ki = 101 nM | [35] | ||
Co-Target Name | Aldo-keto reductase family 1 member C2 (AKR1C2) | Co-Target | ||||
UniProt ID | AK1C2_HUMAN | |||||
Gene Name | AKR1C2 | |||||
Synonyms |
Dihydrodiol dehydrogenase 2; DD-2; DD2; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; Dihydrodiol dehydrogenase/bile acid-binding protein; DD/BABP; Type III 3-alpha-hydroxysteroid dehydrogenase
Click to Show/Hide
|
|||||
Representative Drug(s) | Mefenamic acid | Drug Info | Ki = 220 nM | Click to Show More | [17] | |
2 | Flufenamic Acid | Drug Info | IC50 = 370 nM | [12] | ||
Co-Target Name | Aldo-keto reductase family 1 member B10 (AKR1B10) | Co-Target | ||||
UniProt ID | AK1BA_HUMAN | |||||
Gene Name | AKR1B10 | |||||
Synonyms |
ARL-1; Aldose reductase-like; Aldose reductase-related protein; ARP; hARP; Small intestine reductase; SI reductase
Click to Show/Hide
|
|||||
Representative Drug(s) | Flufenamic Acid | Drug Info | IC50 = 760 nM | [37] | ||
Co-Target Name | Carbonic anhydrase VA (CA5A) | Co-Target | ||||
UniProt ID | CAH5A_HUMAN | |||||
Gene Name | CA5A | |||||
Synonyms |
Carbonic anhydrase 5A, mitochondrial; Carbonate dehydratase VA; CA-VA
Click to Show/Hide
|
|||||
Representative Drug(s) | Celecoxib | Drug Info | Ki = 794 nM | Click to Show More | [6] | |
2 | Valdecoxib | Drug Info | Ki = 912 nM | [6] | ||
Co-Target Name | Aldo-keto reductase family 1 member C1 (AK1C1_HUMAN) | Co-Target | ||||
UniProt ID | AK1C1_HUMAN | |||||
Gene Name | AKR1C1 | |||||
Synonyms |
20-alpha-hydroxysteroid dehydrogenase; 20-alpha-HSD; Dihydrodiol dehydrogenase 1; DD1; Chlordecone reductase homolog HAKRC; High-affinity hepatic bile acid-binding protein; HBAB
Click to Show/Hide
|
|||||
Representative Drug(s) | Mefenamic acid | Drug Info | Ki = 810 nM | [17] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem. 2013 Mar 28;56(6):2429-46. | ||||
REF 2 | Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett. 2002 Feb 25;12(4):533-7. | ||||
REF 3 | Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. J Med Chem. 2003 Jul 31;46(16):3463-75. | ||||
REF 4 | Exploring activity cliffs in medicinal chemistry. J Med Chem. 2012 Apr 12;55(7):2932-42. | ||||
REF 5 | Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007 Apr 5;50(7):1425-41. | ||||
REF 6 | Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit alpha- and beta-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms. J Med Chem. 2012 Nov 26;55(22):9619-29. | ||||
REF 7 | Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety. Bioorg Med Chem. 2013 Oct 1;21(19):5973-82. | ||||
REF 8 | Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004 Jan 29;47(3):550-7. | ||||
REF 9 | Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg Med Chem Lett. 2004 Jan 19;14(2):337-41. | ||||
REF 10 | Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. | ||||
REF 11 | 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1195-8. | ||||
REF 12 | Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem. 2012 Mar 8;55(5):2311-23. | ||||
REF 13 | Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. | ||||
REF 14 | Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J Med Chem. 2016 Aug 25;59(16):7431-44. | ||||
REF 15 | Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects. Bioorg Med Chem. 2017 Apr 1;25(7):2210-7. | ||||
REF 16 | Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J Med Chem. 2013 Jun 13;56(11):4277-99. | ||||
REF 17 | Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. J Med Chem. 2012 Sep 13;55(17):7417-24. | ||||
REF 18 | Syntheses and biological evaluation of two new naproxen analogs. Bioorg Med Chem Lett. 1996 Oct 8;6(19):2281-2. | ||||
REF 19 | Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. | ||||
REF 20 | Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J Med Chem. 1999 Apr 8;42(7):1151-60. | ||||
REF 21 | Neuritogenic activity of bi-functional bis-tryptoline triazole. Bioorg Med Chem. 2017 Feb 1;25(3):1195-1201. | ||||
REF 22 | Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis. ACS Med Chem Lett. 2015 Dec 1;7(1):56-61. | ||||
REF 23 | Recent advances in the discovery and development of glyoxalase I inhibitors. Bioorg Med Chem. 2020 Feb 15;28(4):115243. | ||||
REF 24 | Microbial hydroxylation and glycosylation of pentacyclic triterpenes as inhibitors on tissue factor procoagulant activity. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1026-30. | ||||
REF 25 | Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. J Med Chem. 2005 Oct 6;48(20):6174-7. | ||||
REF 26 | 3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists. J Med Chem. 1989 Aug;32(8):1842-60. | ||||
REF 27 | Targeting microsomal prostaglandin E2 synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Medchemcomm. 2015;6:2081-123. | ||||
REF 28 | Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. J Med Chem. 2016 Jan 14;59(1):194-205. | ||||
REF 29 | The molecular basis for coxib inhibition of p38alpha MAP kinase. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3506-9. | ||||
REF 30 | Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. Bioorg Med Chem. 2018 May 1;26(8):1418-25. | ||||
REF 31 | Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure. J Med Chem. 2017 Aug 10;60(15):6563-6586. | ||||
REF 32 | Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem. 2011 Apr 28;54(8):3037-50. | ||||
REF 33 | Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother. 2007 Dec;51(12):4324-8. | ||||
REF 34 | Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. Eur J Med Chem. 2019 Nov 15;182:111601. | ||||
REF 35 | Identification of small molecules that bind to the mitochondrial protein mitoNEET. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5350-5353. | ||||
REF 36 | Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. Eur J Med Chem. 2017 Oct 20;139:936-946. | ||||
REF 37 | Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. J Nat Prod. 2015 Nov 25;78(11):2666-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.